Study shows direct link between leptin and obesity-related cardiovascular disease

November 10, 2008

ATHENS, Ohio (Nov. 10, 2008) - Obese people who don't have high cholesterol or diabetes might think they're healthy - despite the extra pounds. But new Ohio University research suggests that obesity raises levels of the hormone leptin, which can be as big a threat to the cardiovascular system as cholesterol.

Tadeusz Malinski and colleagues have published the first study to directly observe how high levels of leptin can create a cascade of harmful biochemical changes in the body. Leptin, a peptide hormone produced by fat cells, helps regulate body weight by acting on the hypothalamus to suppress appetite and burn stored fat.

But an excess of fat in the body can produce too much of the hormone, which, in turn, can lower levels of bioavailable nitric oxide. Nitric oxide, produced by the endothelial cells, supports healthy cardiovascular function by relaxing blood vessels and maintaining good blood flow, explained Malinski, who has developed special nanosensors that can detect levels of the substance.

In addition, Malinski found that the high levels of leptin stimulate greater production of superoxide. It reacts with nitric oxide to create peroxynitrite, a very toxic molecule that can impact DNA replication and damage endothelial cells in the vascular system.

"The nanosensors provide a more direct method of determining what processes are occurring in the body. Previously, researchers didn't have a clear idea of how this works," said Malinski, the Marvin and Ann Dilley White Distinguished Professor of Biomedical Sciences at Ohio University.

The study, which examined the process in single human cells and also obese mice models, was published in a recent issue of the American Journal of Physiology - Heart and Circulatory Physiology.

Though obesity is closely associated with heart failure, scientists haven't fully understood the relationship, Malinski noted. The new study suggests that increased levels of leptin alone can cause long-term cardiovascular damage similar to hypertension, arthrosclerosis, diabetes and other disorders.

"Now that we know the exact molecules responsible for the damage, we can design a method to mollify the effect of obesity on the cardiovascular system," Malinski said.
The study was funded by the National Heart, Lung and Blood Institute, the Marvin White Endowment and the Biomimetic Nanoscience and Nanotechnology Program at Ohio University.

Co-authors on the study were Mykhaylo Korda and Ruslan Kubant, both research associates in the Malinski lab at Ohio University.

Contacts: Tadeusz Malinski, (740) 593-1737,; Paula Hale, (740) 597-1219;; Director of Research Communications Andrea Gibson, (740) 597-2166,

Ohio University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to